REGENERON PHARMACEUTIC

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

16 Jan 2024 09:01:13 By NetDania Notify

Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement

16 Jan 2024 06:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

12 Jan 2024 08:45:02 By NetDania Notify

Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024

05 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

04 Jan 2024 12:20:12 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

03 Jan 2024 08:45:09 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

02 Jan 2024 09:17:21 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

27 Dec 2023 12:51:24 By NetDania Notify

Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

18 Dec 2023 15:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

15 Dec 2023 08:46:55 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

13 Dec 2023 08:45:17 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

12 Dec 2023 10:15:14 By NetDania Notify

Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year

11 Dec 2023 06:30:00 By Nasdaq GlobeNewswire

Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes

10 Dec 2023 18:30:00 By Nasdaq GlobeNewswire

Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes

10 Dec 2023 11:30:00 By Nasdaq GlobeNewswire

Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma

07 Dec 2023 06:00:45 By Nasdaq GlobeNewswire

Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO

07 Dec 2023 01:30:59 By Nasdaq GlobeNewswire

Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio

30 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease

27 Nov 2023 00:30:00 By Nasdaq GlobeNewswire

Regeneron Announces Investor Conference Presentation

15 Nov 2023 15:05:00 By Nasdaq GlobeNewswire